{"ticker": {"uuid": "cbdef60c-5d61-466e-a614-1b21fff2df99", "symbol": "AGIO", "name": "Agios Pharm", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Agios Pharmaceuticals (AGIO) Wins Priority Review, Is The Stock Now Fully Valued?", "summary": "Agios Pharmaceuticals' stock is under scrutiny after its mitapivat drug for sickle cell disease received Priority Review from the FDA, leading to a significant 35.51% increase in its share price over 30 days. While analysts' \"fair value\" suggests the stock is still undervalued at", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agio/agios-pharmaceuticals/news/agios-pharmaceuticals-agio-wins-priority-review-is-the-stock/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-15T19:17:08", "published_display": "15 Jul 2026 19:17", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxQSW9mM3I5d1lnaHgzVDlPNFgzSVg3MFNNVmk0N0hLcGh3dko0MF9kWUVzS1phTmdDU1NjUGFZamZZWTBmdnFfanllME9NWmhxd0JiMjJzM3JCQU9SVnY0cEx3T3JnT1pDUlh3Vy0xR1lDem9hZ2ZqdUFXd2UzU1JRbkczUEdHZ1hSRGdTN1JfSHgtLUxQVTBJRjNGbS15Z05pZVd0a25wZl9OX0VjNnp4WHVVOUxxeUVwbTJ1TmdMTzZvcEZVbTkzSDdEUFhvZTdtZC1fb3R2SFZ4ZzQ?oc=5", "source_name": "StockStory", "published_at": "2026-07-15T07:00:00+00:00", "published_display": "15 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Agios Pharmaceuticals (NASDAQ: AGIO) director reports 1,447-share equity award and 2,894 RSUs", "summary": "Agios Pharmaceuticals director Jay T. Backstrom reported acquiring 1,447 shares of common stock through the vesting of restricted stock units (RSUs) on July 8, 2026. After this transaction, he directly holds 1,447 common shares and still has 2,894 RSUs outstanding. The RSUs were ", "url": "https://www.stocktitan.net/sec-filings/AGIO/form-4-agios-pharmaceuticals-inc-insider-trading-activity-2141552270d9.html", "source_name": "Stock Titan", "published_at": "2026-07-10T20:40:32", "published_display": "10 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Priority Review Sends Agios Pharmaceuticals (NASDAQ: AGIO) Stock Price Surging 13.8% As Sickle Cell Drug Gains Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_AFBVV95cUxOY1hEMmlSVm94a1p3NC13S19ISWJEbERfMXoydVR4NGF6Yno5U1ViODNPNDZWU2ZhQjNkTTM0S2FqZVdZQVdOTVRvRERXVm5WM3FER0c3Q3JQZURhMzIyX3d5NS15MkZhX29aMDhSWHhWbzcyOHJYNktfWEFqWlphbmwyazZfWDlTT2V2M2k2WkFDRVA1SUwwX1hQV0JMeHZCM3EyQXFsOXEyb21FVXpGaDNhUWJza2lyc05pQ2RCc2M5WUZkREhnVDJkeEw4aXItRzV5enktTEtXbzdwR1RiR051QUZXdnV1QmlqamctYmRaanRzMlZnWEpNOXA?oc=5", "source_name": "foreignpolicyjournal.com", "published_at": "2026-07-10T18:03:00+00:00", "published_display": "10 Jul 2026 18:03", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why Shares in Novo Nordisk Rival, Agios Pharmaceutical, Soared This Week", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTGE4cEtnd3FRTHNqdzdxd3NXbDFfQzM1WjlYeXlIbVg2ZlhWeFJuRHpEVHg1cFUzV2NaVDEtT2FaYnFraGxncjJ6SnBoRXA4WENzcjl6TUlWUXBuQ0FlZUVjQ0tjaWdNZW5IT09LX0NKc2drR09WeEpKU0JrazlLczlOZVhrTUFWbVM1WWlQTTBha19DclRadQ?oc=5", "source_name": "The Motley Fool", "published_at": "2026-07-10T12:35:00+00:00", "published_display": "10 Jul 2026 12:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Agios Pharmaceuticals (AGIO) A Bargain After FDA Priority Review For Mitapivat?", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/agios-pharmaceuticals-agio-bargain-fda-121327173.html", "source_name": "Simply Wall St.", "published_at": "2026-07-09T12:13:27+00:00", "published_display": "09 Jul 2026 12:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agios gains FDA priority review for Pyrukynd label expansion", "summary": "NULL", "url": "https://www.msn.com/en-us/health/other/agios-gains-fda-priority-review-for-pyrukynd-label-expansion/ar-AA27oL45", "source_name": "MSN", "published_at": "2026-07-09T11:40:57", "published_display": "09 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agios Pharmaceuticals (AGIO) Is Up 13.8% After FDA Grants Priority Review To Mitapivat In Sickle Cell Disease", "summary": "Agios Pharmaceuticals' stock (AGIO) rose 13.8% after the FDA granted Priority Review to its supplemental New Drug Application for mitapivat in sickle cell disease, setting a PDUFA goal date of November 1, 2026. This move expands on mitapivat's existing approvals and highlights Ag", "url": "https://finance.yahoo.com/healthcare/articles/agios-pharmaceuticals-agio-13-8-101344258.html", "source_name": "Market source", "published_at": "2026-07-09T10:40:56", "published_display": "09 Jul 2026 10:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Agios Pharma Stock Soaring Tuesday?", "summary": "Agios Pharmaceuticals' stock surged over 15% after the FDA accepted its supplemental New Drug Application for mitapivat in sickle cell disease with Priority Review, setting a PDUFA goal date of November 1. This positive news led several Wall Street firms, including Truist Securit", "url": "https://www.sahmcapital.com/news/content/why-is-agios-pharma-stock-soaring-tuesday-2026-07-07", "source_name": "Sahm", "published_at": "2026-07-09T00:39:38", "published_display": "09 Jul 2026 00:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AGIO's Filing for Mitapivat in SCD Gets FDA's Priority Tag, Stock Up", "summary": "Agios Pharmaceuticals (AGIO) announced that the FDA has accepted its supplemental new drug application (sNDA) for mitapivat, an oral pyruvate kinase activator, for the treatment of sickle cell disease (SCD), granting it priority review. A decision is expected by November 1, 2026.", "url": "https://www.theglobeandmail.com/investing/markets/stocks/LQDA/pressreleases/3187613/agios-filing-for-mitapivat-in-scd-gets-fdas-priority-tag-stock-up/", "source_name": "The Globe and Mail", "published_at": "2026-07-08T15:40:57", "published_display": "08 Jul 2026 15:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BofA Securities Adjusts Price Target on Agios Pharmaceuticals to $46 From $40, Maintains Buy Rating", "summary": "BofA Securities has increased its price target for Agios Pharmaceuticals (AGIO) to $46 from $40, while reaffirming a Buy rating on the stock. This adjustment reflects a positive outlook from the firm regarding Agios Pharmaceuticals' financial prospects and market valuation.", "url": "https://www.moomoo.com/news/post/72591959/bofa-securities-adjusts-price-target-on-agios-pharmaceuticals-to-46", "source_name": "Moomoo", "published_at": "2026-07-08T11:39:39", "published_display": "08 Jul 2026 11:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Strength Seen in Agios Pharmaceuticals (AGIO): Can Its 17.7% Jump Turn into More Strength?", "summary": "Agios Pharmaceuticals (AGIO) shares surged 17.7% after the FDA granted priority review to its supplemental new drug application for mitapivat to treat sickle cell disease, with a decision expected by November 1, 2026. Despite this jump, the stock carries a Zacks Rank #3 (Hold) du", "url": "https://finance.yahoo.com/markets/stocks/articles/strength-seen-agios-pharmaceuticals-agio-142900682.html", "source_name": "Market source", "published_at": "2026-07-08T10:29:00", "published_display": "08 Jul 2026 10:29", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $54", "summary": "H.C. Wainwright has reaffirmed its Buy rating for Agios Pharmaceuticals (AGIO.US) and maintained its target price at $54. This indicates a continued positive outlook from the analytical firm regarding the company's stock performance.", "url": "https://www.moomoo.com/news/post/72596212/hc-wainwright-maintains-agios-pharmaceuticals-agious-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-07-08T07:39:12", "published_display": "08 Jul 2026 07:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "After receiving priority review designation from the FDA for its sickle cell disease treatment, Agios Pharmaceuticals, Inc. shares surged by 12.4%.", "summary": "Agios Pharmaceuticals, Inc. experienced a 12.4% surge in its share price following the FDA's designation of priority review for its sickle cell disease treatment. This regulatory fast-tracking shortens the drug review timeline, potentially leading to an accelerated market launch.", "url": "https://www.bitget.com/asia/amp/news/detail/12560605494071", "source_name": "Bitget", "published_at": "2026-07-07T23:40:32", "published_display": "07 Jul 2026 23:40", "sentiment": "positive", "sentiment_pct": 93, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agios Pharmaceuticals (NASDAQ:AGIO) pops as FDA review moves price above average target", "summary": "Agios Pharmaceuticals (AGIO) saw its stock price jump 14.9% to $42.95 after the FDA granted Priority Review for its mitapivat application for sickle cell disease. This pushed the stock 9.2% above Google Finance's average 12-month target of $39.33, with a PDUFA date set for Novemb", "url": "https://ts2.tech/en/agios-pharmaceuticals-nasdaqagio-pops-as-fda-review-moves-price-above-average-target/", "source_name": "TechStock\u00b2", "published_at": "2026-07-07T19:10:43", "published_display": "07 Jul 2026 19:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why Agios Pharmaceuticals Stock Soared Today (Hint: It's FDA-Related)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxOakJiYUhSdWtYV2Y0Nlg2am1yRGw2bzA4cU1ScWZjUWI0WFpjU3YxeTlmSFRFZEZNWnRMSy1kMjBHSXFPWkY5UHZxWTBqNXhJUjZqS2JYQW9DZmNDWHliTDVtWFB3eVN6Qkhic2gxWTA2clhCU0xjNXQzZE12R25UQlNkZHV1Vi04?oc=5", "source_name": "AOL.com", "published_at": "2026-07-07T17:14:12+00:00", "published_display": "07 Jul 2026 17:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AGIO Stock Jumps As Mitapivat Sickle Cell Data Fuels Hype", "summary": "Agios Pharmaceuticals Inc. (AGIO) saw its stock jump by over 16% due to positive 52-week Phase 3 RISE UP mitapivat data for sickle cell disease, which showed durable hemoglobin gains and a clean safety profile. This strong clinical data supports an accelerated FDA review for mita", "url": "https://stockstotrade.com/news/agios-pharmaceuticals-inc-agio-news-2026_07_07/", "source_name": "StocksToTrade", "published_at": "2026-07-07T16:10:43", "published_display": "07 Jul 2026 16:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moderna, TG Therapeutics, Agios Pharmaceuticals Q2 Results May Face Increased Scrutiny, BofA Says", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/moderna-tg-therapeutics-agios-pharmaceuticals-150415176.html", "source_name": "MT Newswires", "published_at": "2026-07-07T15:04:15+00:00", "published_display": "07 Jul 2026 15:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is Agios Pharm stock rallying today? By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPZ3FsRDRGQUFYU1g4Q2xUUGwzZ1RSb3Z5VndySFJ5T3l6VG9DdlRxVV9GOEZaeVBBTG9KaUU2WlZuZnJrQWM5cWQxQmlDeXV6ekRkWEp6bGJiZ3FYZV9FVjZtMGZlVDVKbkVxOFZDZEd1NzlPTm1EVE8xYTdzZUVDd3FBRU5XN2tVZ1NCRFR6WTNmbkI0c2dXTUp3TXk2RFFWVlE?oc=5", "source_name": "Investing.com South Africa", "published_at": "2026-07-07T13:49:37+00:00", "published_display": "07 Jul 2026 13:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA accepts Agios sNDA for mitapivat in sickle cell disease", "summary": "Agios Pharmaceuticals announced that the FDA has accepted its supplemental New Drug Application (sNDA) for mitapivat in sickle cell disease with a Priority Review designation, setting a PDUFA goal date of November 1, 2026. This designation shortens the review period to six months", "url": "https://www.investing.com/news/company-news/fda-accepts-agios-snda-for-mitapivat-in-sickle-cell-disease-93CH-4778788", "source_name": "Investing.com", "published_at": "2026-07-07T12:10:43", "published_display": "07 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Agios Pharmaceuticals, Inc. \u2013 DUS:8AP", "summary": "This article focuses on the \"Price to sales forward\" financial metric for Agios Pharmaceuticals, Inc. (DUS:8AP) on the Dusseldorf Stock Exchange. It appears to be a stub or a section of a larger financial data platform, indicating where this specific financial data point can be f", "url": "https://www.tradingview.com/symbols/DUS-8AP/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T11:39:12", "published_display": "07 Jul 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA puts Agios' sickle cell drug on fast track to Nov. 1 review date", "summary": "The FDA has granted Priority Review to Agios Pharmaceuticals' supplemental New Drug Application (sNDA) for mitapivat in sickle cell disease, with a PDUFA goal date of November 1, 2026. This fast-track designation, under the accelerated approval pathway, aims to address the signif", "url": "https://www.stocktitan.net/news/AGIO/u-s-fda-grants-priority-review-to-agios-s-nda-for-mitapivat-in-wxy64e3mxywh.html", "source_name": "Stock Titan", "published_at": "2026-07-07T10:00:29", "published_display": "07 Jul 2026 10:00", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Agios Pharmaceuticals, Inc. \u2013 MUN:8AP", "summary": "This article provides a financial overview of Agios Pharmaceuticals, Inc. (MUN:8AP) on the Munich Stock Exchange, specifically focusing on its price to sales forward ratio. The page indicates no recent trades and offers various financial data, news, community forums, and forecast", "url": "https://www.tradingview.com/symbols/MUN-8AP/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T05:09:29", "published_display": "07 Jul 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agios Pharmaceuticals (AGIO) Could Be 8% Below Fair Value On Growth Index Shift", "summary": "Agios Pharmaceuticals (AGIO) has been reclassified into several Russell growth indices following a strong recent performance in its share price. Despite this shift, the company is still considered modestly undervalued with a fair value of $40.88 against a last close of $37.58, dr", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agio/agios-pharmaceuticals/news/agios-pharmaceuticals-agio-could-be-8-below-fair-value-on-gr", "source_name": "Simply Wall Street", "published_at": "2026-07-06T11:09:29", "published_display": "06 Jul 2026 11:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Technical Signals Behind (AGIO) That Institutions Follow", "summary": "This article analyzes Agios Pharmaceuticals Inc. (NASDAQ: AGIO), highlighting strong near and mid-term sentiment but a weak long-term outlook. It identifies no resistance levels above the current price, suggesting upside potential. The piece provides AI-generated trading strategi", "url": "https://news.stocktradersdaily.com/news_release/132/The_Technical_Signals_Behind_AGIO_That_Institutions_Follow_070526055602_1783288562.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-05T17:56:00", "published_display": "05 Jul 2026 17:56", "sentiment": "positive", "sentiment_pct": 65, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Agios Pharmaceuticals, Inc. \u2013 NASDAQ:AGIO", "summary": "The article provides financial data on Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), specifically its price to book forward metric. It also lists various financial tools and resources available on TradingView, covering markets, community features, and business solutions.", "url": "https://www.tradingview.com/symbols/NASDAQ-AGIO/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T06:10:19", "published_display": "05 Jul 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AGIO - Agios Pharmaceuticals Inc Latest SEC Filings", "summary": "This page provides the latest SEC filings for Agios Pharmaceuticals Inc (AGIO), including financial data, trading performance metrics, and key company statistics. It details market capitalization, income, sales, various ratios, analyst recommendations, and recent stock performanc", "url": "https://finviz.com/stock?t=AGIO&ta=1&p=d&ty=lf&b=2&r=m6&page=27", "source_name": "Finviz", "published_at": "2026-07-04T10:10:19", "published_display": "04 Jul 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Agios Pharmaceuticals, Inc. \u2013 NASDAQ:AGIO", "summary": "This page provides financial information for Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), specifically its price-to-earnings forward ratio. It highlights that the market is closed, with no trades, and offers various data points and resources related to the company's financials on ", "url": "https://www.tradingview.com/symbols/NASDAQ-AGIO/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-03T11:39:42", "published_display": "03 Jul 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Agios Pharm For: 2 July By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPR0FfUlAtRTdBVE1qZVo5VnlCN3FCbWtIUjE0Y29jTzJhRTlUMm1YTkVnNjFBSzI3amN1bUI1elp3VTB5NUJHUUFZVGFqUDNhajVqUDhoYlVJeF9QVy1tc0ZjN1lraEE2dTRaREpoUkFGa0UzTTBOV0treThIRWYtLWpReXNoN2pQa2ZrQ0Fzc3gzY0d6?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-07-02T22:02:56+00:00", "published_display": "02 Jul 2026 22:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agios Pharmaceuticals: CMO Sarah Gheuens sells $150,502 in stock By Investing.com", "summary": "Sarah Gheuens, CMO of Agios Pharmaceuticals, sold 4,007 shares of company stock worth $150,502 to cover tax obligations related to restricted stock unit vesting. This transaction followed a 10b5-1 trading plan established in 2023. Gheuens simultaneously acquired 8,375 shares thro", "url": "https://ca.investing.com/news/stock-market-news/agios-pharmaceuticals-cmo-sarah-gheuens-sells-150502-in-stock-93CH-4718904", "source_name": "Investing.com Canada", "published_at": "2026-07-02T20:11:49", "published_display": "02 Jul 2026 20:11", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agios (NASDAQ: AGIO) CMO nets shares after RSU vesting and tax sale", "summary": "Agios Pharmaceuticals' Chief Medical Officer, Sarah Gheuens, reported a routine equity transaction where 8,375 restricted stock units vested and converted into common shares. To cover tax obligations, 4,007 shares were sold at $37.56 each under a pre-arranged 10b5-1 plan. Followi", "url": "https://www.stocktitan.net/sec-filings/AGIO/form-4-agios-pharmaceuticals-inc-insider-trading-activity-b939195679ee.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:09:49", "published_display": "02 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "D. E. Shaw reports 3.03M-share stake in Agios (AGIO)", "summary": "D. E. Shaw & Co., L.P. and David E. Shaw have reported a 5.1% stake in Agios Pharmaceuticals (AGIO), totaling 3,034,031 shares, through a Schedule 13G SEC filing. The filing indicates shared voting power over 2,863,931 shares and shared dispositive power over all 3,034,031 shares", "url": "https://www.stocktitan.net/sec-filings/AGIO/schedule-13g-agios-pharmaceuticals-inc-passive-investment-disclosure--4fb451f2ba1d.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:09:49", "published_display": "02 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AGIO (NASDAQ: AGIO) affiliate notifies plan to offer 4,007 shares via broker", "summary": "An affiliate of Agios Pharmaceuticals (NASDAQ: AGIO) has filed a Form 144, indicating a plan to offer 4,007 shares of common stock. These shares are associated with the vesting of restricted stock units on July 1, 2026, and will be sold through Morgan Stanley Smith Barney LLC. Th", "url": "https://www.stocktitan.net/sec-filings/AGIO/144-agios-pharmaceuticals-inc-sec-filing-6eb6c2d7e508.html", "source_name": "Stock Titan", "published_at": "2026-07-01T19:41:17", "published_display": "01 Jul 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Agios Pharmaceuticals' Shift Into Russell Growth Indices Will Impact Agios Pharmaceuticals (AGIO) Investors", "summary": "Agios Pharmaceuticals (AGIO) has been added to several Russell growth benchmarks, including the Russell 2000 Growth, indicating an increasing perception of the company as a growth-oriented biotech. This reclassification could attract more growth-focused institutional investors an", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agio/agios-pharmaceuticals/news/how-agios-pharmaceuticals-shift-into-russell-growth-indices/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-01T08:41:17", "published_display": "01 Jul 2026 08:41", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agios (NASDAQ: AGIO) director exercises RSUs and gains new equity awards", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOXzZjUlhjaTlTdk5YZW1SM09FVmR3dVZkam05TWlTekM4dk1mTDRhR09sR29UbHlJMElSSFV5T05YelAxc0NGYkJWTDVxZ19MUmttRmRrVVhrUW1vYlpjSWRvM3JKOUNXS0FDbV9ZelNhSGowb3o3TkltUzBqYzFTTENjY05VN2d4SUUwaVhDbjNpSV9GaC1RYmVXSVp6ZGR6MG5VUExveGlTczlxSjBRRUlzOS1mMDdDNXo0?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Agios Pharmaceuticals (AGIO) Valuation After Recent Share Price Volatility", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNNWZDVzRRdFhPdUNuajRBTGdab2tWdXBqMU5od3l5X1NVZndKQXo5eGNQaExPSF8wNGJVbElzSC0wSlpJdjJ4ZlNGRWpDcnUzcWZMMEw4ekJNMGVEcnZBSDRxT1ZrcmczRWp5R2JLQ1BZMEpGRVI2SlBJV2JvQkdjc1lNTlAwQmJQWEtXN2tvblV6OTBpQ3daRHdXQ3VtbExfZHVxcTQwckhCeVFlbXpIag?oc=5", "source_name": "Market source", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Agios submits application for mitapivat in sickle cell disease", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOcllsby0zMFpBUjVtaUdDS3lOQUhxQzdaTjNyUmtndWU1SG1DeUhYYnUyMXloaXV1OFJjXzdMa0VxdDZGYWhWYUF0VTlUUVBRRTRlMnY3Z3l3eUF4YVhYcW1wYlZpMzdEWVJkdV9iTFdSeHhQRGhaWnI3eFIweldBSTh5QklVMmJxb3Z1MWtsQ1ZrZXZNV2ZldEJJNUo4TlNHS0xfeVExMFQ1d1lwR3ZsbFZlNVdXYWJzWkhn?oc=5", "source_name": "Investing.com", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agios presents mitapivat data at European hematology congress", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxObFVNb2FiQVZjNG5XODhNY1BpU05NOXBnQWxUR25qT2VmaUNCRTZGeUE3eThrY09NaEM0OU5QU0N4X1h5YWpyeFl1MGdWaHJTV3hnOFQ4Y1VsTjc5dXZfWDdMV2hMQldlcktQNEloUXN3LU1UQ05xdHdacExQRHhINWFRM2YwUFE1WjJLei11dzdfR3IzTmFvVm5Qb250bXNtdjNJVTIzM0MwYTJENUVPT0pVdHpIQVQ4THc?oc=5", "source_name": "Investing.com", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Agios Pharmaceuticals stock tumbles 25% after Novo data", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNMkZZMHByQ1JydDhyOFFsdkFVY1hIVGl6dXFkSzZ2RWZ2U25FQWxxTFFWSHA5VzNHby1sOVlseXFZanZuTVBiU25CckZ6YXJwaV9yQzZDMTl2cTMtYmFoOW96UGo4TnA5M3BVTjFjdUZZSGlDZDU1akl5RzlMaWRVejJHX2h4S01tc19ya01vLUk0azFpOEt6S1RfU3lCYWktVHRJM3VKdVdmWFhiOThlcA?oc=5", "source_name": "Investing.com", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why Agios Pharmaceuticals Crashed 23% Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPTFhIUTFtdjVxZ1lvcm5rdzFSS2dGaVNBZjdBNTF4TUV6Njc3WEljbkFqVWl2a2JRdk9ZMVlCU3NlLXZrQndJV3lPZDdvOUF3d1Znc0FmX01ybERCTnpHbWx6SldvR2xQNWRfVHNkSGlmWkw3c3B1VXd4M1ZyZUFTaWtkeS1WUkpvU3dwM2ZESkZkREpzNXc?oc=5", "source_name": "The Motley Fool", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings call transcript: Agios Pharm Q4 2024 beats EPS forecast, stock rises", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxQVTQ2S0huX2dvUkVwTEFZTEJoZmJ6c1hkcDV3VUl5a0k5eXlxY2hoS2VfbDdsLUJCaFlBODFFTVVoeWF5R1pvc2tpMWlPcjI2R0NaVVhXb0JNNVdBeE5HbWJ2clBHYm90YzRuUFJSSTFvaWpUVnc0Q243dnZqenZmSzUyY3pDMXI5dW9jVUVGVFpmbWNyMXlVSHFWNW4wWWo4U0xmZzRXaldxbDZVQ3VnZ3NQeUZTN08yTkQ3TFhXQlNKSTFncFFxRUVB?oc=5", "source_name": "Investing.com UK", "published_at": "2025-02-13T08:00:00+00:00", "published_display": "13 Feb 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Agios Pharmaceuticals (AGIO) Wins Priority Review, Is The Stock Now Fully Valued?", "summary": "Agios Pharmaceuticals' stock is under scrutiny after its mitapivat drug for sickle cell disease received Priority Review from the FDA, leading to a significant 35.51% increase in its share price over 30 days. While analysts' \"fair value\" suggests the stock is still undervalued at", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agio/agios-pharmaceuticals/news/agios-pharmaceuticals-agio-wins-priority-review-is-the-stock/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-15T19:17:08", "published_display": "15 Jul 2026 19:17", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agios Pharmaceuticals (NASDAQ: AGIO) director reports 1,447-share equity award and 2,894 RSUs", "summary": "Agios Pharmaceuticals director Jay T. Backstrom reported acquiring 1,447 shares of common stock through the vesting of restricted stock units (RSUs) on July 8, 2026. After this transaction, he directly holds 1,447 common shares and still has 2,894 RSUs outstanding. The RSUs were ", "url": "https://www.stocktitan.net/sec-filings/AGIO/form-4-agios-pharmaceuticals-inc-insider-trading-activity-2141552270d9.html", "source_name": "Stock Titan", "published_at": "2026-07-10T20:40:32", "published_display": "10 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Priority Review Sends Agios Pharmaceuticals (NASDAQ: AGIO) Stock Price Surging 13.8% As Sickle Cell Drug Gains Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_AFBVV95cUxOY1hEMmlSVm94a1p3NC13S19ISWJEbERfMXoydVR4NGF6Yno5U1ViODNPNDZWU2ZhQjNkTTM0S2FqZVdZQVdOTVRvRERXVm5WM3FER0c3Q3JQZURhMzIyX3d5NS15MkZhX29aMDhSWHhWbzcyOHJYNktfWEFqWlphbmwyazZfWDlTT2V2M2k2WkFDRVA1SUwwX1hQV0JMeHZCM3EyQXFsOXEyb21FVXpGaDNhUWJza2lyc05pQ2RCc2M5WUZkREhnVDJkeEw4aXItRzV5enktTEtXbzdwR1RiR051QUZXdnV1QmlqamctYmRaanRzMlZnWEpNOXA?oc=5", "source_name": "foreignpolicyjournal.com", "published_at": "2026-07-10T18:03:00+00:00", "published_display": "10 Jul 2026 18:03", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why Shares in Novo Nordisk Rival, Agios Pharmaceutical, Soared This Week", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTGE4cEtnd3FRTHNqdzdxd3NXbDFfQzM1WjlYeXlIbVg2ZlhWeFJuRHpEVHg1cFUzV2NaVDEtT2FaYnFraGxncjJ6SnBoRXA4WENzcjl6TUlWUXBuQ0FlZUVjQ0tjaWdNZW5IT09LX0NKc2drR09WeEpKU0JrazlLczlOZVhrTUFWbVM1WWlQTTBha19DclRadQ?oc=5", "source_name": "The Motley Fool", "published_at": "2026-07-10T12:35:00+00:00", "published_display": "10 Jul 2026 12:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Agios Pharmaceuticals (AGIO) A Bargain After FDA Priority Review For Mitapivat?", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/agios-pharmaceuticals-agio-bargain-fda-121327173.html", "source_name": "Simply Wall St.", "published_at": "2026-07-09T12:13:27+00:00", "published_display": "09 Jul 2026 12:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agios gains FDA priority review for Pyrukynd label expansion", "summary": "NULL", "url": "https://www.msn.com/en-us/health/other/agios-gains-fda-priority-review-for-pyrukynd-label-expansion/ar-AA27oL45", "source_name": "MSN", "published_at": "2026-07-09T11:40:57", "published_display": "09 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agios Pharmaceuticals (AGIO) Is Up 13.8% After FDA Grants Priority Review To Mitapivat In Sickle Cell Disease", "summary": "Agios Pharmaceuticals' stock (AGIO) rose 13.8% after the FDA granted Priority Review to its supplemental New Drug Application for mitapivat in sickle cell disease, setting a PDUFA goal date of November 1, 2026. This move expands on mitapivat's existing approvals and highlights Ag", "url": "https://finance.yahoo.com/healthcare/articles/agios-pharmaceuticals-agio-13-8-101344258.html", "source_name": "Market source", "published_at": "2026-07-09T10:40:56", "published_display": "09 Jul 2026 10:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Agios Pharma Stock Soaring Tuesday?", "summary": "Agios Pharmaceuticals' stock surged over 15% after the FDA accepted its supplemental New Drug Application for mitapivat in sickle cell disease with Priority Review, setting a PDUFA goal date of November 1. This positive news led several Wall Street firms, including Truist Securit", "url": "https://www.sahmcapital.com/news/content/why-is-agios-pharma-stock-soaring-tuesday-2026-07-07", "source_name": "Sahm", "published_at": "2026-07-09T00:39:38", "published_display": "09 Jul 2026 00:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AGIO's Filing for Mitapivat in SCD Gets FDA's Priority Tag, Stock Up", "summary": "Agios Pharmaceuticals (AGIO) announced that the FDA has accepted its supplemental new drug application (sNDA) for mitapivat, an oral pyruvate kinase activator, for the treatment of sickle cell disease (SCD), granting it priority review. A decision is expected by November 1, 2026.", "url": "https://www.theglobeandmail.com/investing/markets/stocks/LQDA/pressreleases/3187613/agios-filing-for-mitapivat-in-scd-gets-fdas-priority-tag-stock-up/", "source_name": "The Globe and Mail", "published_at": "2026-07-08T15:40:57", "published_display": "08 Jul 2026 15:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BofA Securities Adjusts Price Target on Agios Pharmaceuticals to $46 From $40, Maintains Buy Rating", "summary": "BofA Securities has increased its price target for Agios Pharmaceuticals (AGIO) to $46 from $40, while reaffirming a Buy rating on the stock. This adjustment reflects a positive outlook from the firm regarding Agios Pharmaceuticals' financial prospects and market valuation.", "url": "https://www.moomoo.com/news/post/72591959/bofa-securities-adjusts-price-target-on-agios-pharmaceuticals-to-46", "source_name": "Moomoo", "published_at": "2026-07-08T11:39:39", "published_display": "08 Jul 2026 11:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Strength Seen in Agios Pharmaceuticals (AGIO): Can Its 17.7% Jump Turn into More Strength?", "summary": "Agios Pharmaceuticals (AGIO) shares surged 17.7% after the FDA granted priority review to its supplemental new drug application for mitapivat to treat sickle cell disease, with a decision expected by November 1, 2026. Despite this jump, the stock carries a Zacks Rank #3 (Hold) du", "url": "https://finance.yahoo.com/markets/stocks/articles/strength-seen-agios-pharmaceuticals-agio-142900682.html", "source_name": "Market source", "published_at": "2026-07-08T10:29:00", "published_display": "08 Jul 2026 10:29", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $54", "summary": "H.C. Wainwright has reaffirmed its Buy rating for Agios Pharmaceuticals (AGIO.US) and maintained its target price at $54. This indicates a continued positive outlook from the analytical firm regarding the company's stock performance.", "url": "https://www.moomoo.com/news/post/72596212/hc-wainwright-maintains-agios-pharmaceuticals-agious-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-07-08T07:39:12", "published_display": "08 Jul 2026 07:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "After receiving priority review designation from the FDA for its sickle cell disease treatment, Agios Pharmaceuticals, Inc. shares surged by 12.4%.", "summary": "Agios Pharmaceuticals, Inc. experienced a 12.4% surge in its share price following the FDA's designation of priority review for its sickle cell disease treatment. This regulatory fast-tracking shortens the drug review timeline, potentially leading to an accelerated market launch.", "url": "https://www.bitget.com/asia/amp/news/detail/12560605494071", "source_name": "Bitget", "published_at": "2026-07-07T23:40:32", "published_display": "07 Jul 2026 23:40", "sentiment": "positive", "sentiment_pct": 93, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agios Pharmaceuticals (NASDAQ:AGIO) pops as FDA review moves price above average target", "summary": "Agios Pharmaceuticals (AGIO) saw its stock price jump 14.9% to $42.95 after the FDA granted Priority Review for its mitapivat application for sickle cell disease. This pushed the stock 9.2% above Google Finance's average 12-month target of $39.33, with a PDUFA date set for Novemb", "url": "https://ts2.tech/en/agios-pharmaceuticals-nasdaqagio-pops-as-fda-review-moves-price-above-average-target/", "source_name": "TechStock\u00b2", "published_at": "2026-07-07T19:10:43", "published_display": "07 Jul 2026 19:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why Agios Pharmaceuticals Stock Soared Today (Hint: It's FDA-Related)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxOakJiYUhSdWtYV2Y0Nlg2am1yRGw2bzA4cU1ScWZjUWI0WFpjU3YxeTlmSFRFZEZNWnRMSy1kMjBHSXFPWkY5UHZxWTBqNXhJUjZqS2JYQW9DZmNDWHliTDVtWFB3eVN6Qkhic2gxWTA2clhCU0xjNXQzZE12R25UQlNkZHV1Vi04?oc=5", "source_name": "AOL.com", "published_at": "2026-07-07T17:14:12+00:00", "published_display": "07 Jul 2026 17:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AGIO Stock Jumps As Mitapivat Sickle Cell Data Fuels Hype", "summary": "Agios Pharmaceuticals Inc. (AGIO) saw its stock jump by over 16% due to positive 52-week Phase 3 RISE UP mitapivat data for sickle cell disease, which showed durable hemoglobin gains and a clean safety profile. This strong clinical data supports an accelerated FDA review for mita", "url": "https://stockstotrade.com/news/agios-pharmaceuticals-inc-agio-news-2026_07_07/", "source_name": "StocksToTrade", "published_at": "2026-07-07T16:10:43", "published_display": "07 Jul 2026 16:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moderna, TG Therapeutics, Agios Pharmaceuticals Q2 Results May Face Increased Scrutiny, BofA Says", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/moderna-tg-therapeutics-agios-pharmaceuticals-150415176.html", "source_name": "MT Newswires", "published_at": "2026-07-07T15:04:15+00:00", "published_display": "07 Jul 2026 15:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is Agios Pharm stock rallying today? By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPZ3FsRDRGQUFYU1g4Q2xUUGwzZ1RSb3Z5VndySFJ5T3l6VG9DdlRxVV9GOEZaeVBBTG9KaUU2WlZuZnJrQWM5cWQxQmlDeXV6ekRkWEp6bGJiZ3FYZV9FVjZtMGZlVDVKbkVxOFZDZEd1NzlPTm1EVE8xYTdzZUVDd3FBRU5XN2tVZ1NCRFR6WTNmbkI0c2dXTUp3TXk2RFFWVlE?oc=5", "source_name": "Investing.com South Africa", "published_at": "2026-07-07T13:49:37+00:00", "published_display": "07 Jul 2026 13:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA accepts Agios sNDA for mitapivat in sickle cell disease", "summary": "Agios Pharmaceuticals announced that the FDA has accepted its supplemental New Drug Application (sNDA) for mitapivat in sickle cell disease with a Priority Review designation, setting a PDUFA goal date of November 1, 2026. This designation shortens the review period to six months", "url": "https://www.investing.com/news/company-news/fda-accepts-agios-snda-for-mitapivat-in-sickle-cell-disease-93CH-4778788", "source_name": "Investing.com", "published_at": "2026-07-07T12:10:43", "published_display": "07 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Agios Pharmaceuticals, Inc. \u2013 DUS:8AP", "summary": "This article focuses on the \"Price to sales forward\" financial metric for Agios Pharmaceuticals, Inc. (DUS:8AP) on the Dusseldorf Stock Exchange. It appears to be a stub or a section of a larger financial data platform, indicating where this specific financial data point can be f", "url": "https://www.tradingview.com/symbols/DUS-8AP/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T11:39:12", "published_display": "07 Jul 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA puts Agios' sickle cell drug on fast track to Nov. 1 review date", "summary": "The FDA has granted Priority Review to Agios Pharmaceuticals' supplemental New Drug Application (sNDA) for mitapivat in sickle cell disease, with a PDUFA goal date of November 1, 2026. This fast-track designation, under the accelerated approval pathway, aims to address the signif", "url": "https://www.stocktitan.net/news/AGIO/u-s-fda-grants-priority-review-to-agios-s-nda-for-mitapivat-in-wxy64e3mxywh.html", "source_name": "Stock Titan", "published_at": "2026-07-07T10:00:29", "published_display": "07 Jul 2026 10:00", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Agios Pharmaceuticals, Inc. \u2013 MUN:8AP", "summary": "This article provides a financial overview of Agios Pharmaceuticals, Inc. (MUN:8AP) on the Munich Stock Exchange, specifically focusing on its price to sales forward ratio. The page indicates no recent trades and offers various financial data, news, community forums, and forecast", "url": "https://www.tradingview.com/symbols/MUN-8AP/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T05:09:29", "published_display": "07 Jul 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agios Pharmaceuticals (AGIO) Could Be 8% Below Fair Value On Growth Index Shift", "summary": "Agios Pharmaceuticals (AGIO) has been reclassified into several Russell growth indices following a strong recent performance in its share price. Despite this shift, the company is still considered modestly undervalued with a fair value of $40.88 against a last close of $37.58, dr", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agio/agios-pharmaceuticals/news/agios-pharmaceuticals-agio-could-be-8-below-fair-value-on-gr", "source_name": "Simply Wall Street", "published_at": "2026-07-06T11:09:29", "published_display": "06 Jul 2026 11:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Technical Signals Behind (AGIO) That Institutions Follow", "summary": "This article analyzes Agios Pharmaceuticals Inc. (NASDAQ: AGIO), highlighting strong near and mid-term sentiment but a weak long-term outlook. It identifies no resistance levels above the current price, suggesting upside potential. The piece provides AI-generated trading strategi", "url": "https://news.stocktradersdaily.com/news_release/132/The_Technical_Signals_Behind_AGIO_That_Institutions_Follow_070526055602_1783288562.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-05T17:56:00", "published_display": "05 Jul 2026 17:56", "sentiment": "positive", "sentiment_pct": 65, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Agios Pharmaceuticals, Inc. \u2013 NASDAQ:AGIO", "summary": "The article provides financial data on Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), specifically its price to book forward metric. It also lists various financial tools and resources available on TradingView, covering markets, community features, and business solutions.", "url": "https://www.tradingview.com/symbols/NASDAQ-AGIO/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T06:10:19", "published_display": "05 Jul 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AGIO - Agios Pharmaceuticals Inc Latest SEC Filings", "summary": "This page provides the latest SEC filings for Agios Pharmaceuticals Inc (AGIO), including financial data, trading performance metrics, and key company statistics. It details market capitalization, income, sales, various ratios, analyst recommendations, and recent stock performanc", "url": "https://finviz.com/stock?t=AGIO&ta=1&p=d&ty=lf&b=2&r=m6&page=27", "source_name": "Finviz", "published_at": "2026-07-04T10:10:19", "published_display": "04 Jul 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Agios Pharmaceuticals, Inc. \u2013 NASDAQ:AGIO", "summary": "This page provides financial information for Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), specifically its price-to-earnings forward ratio. It highlights that the market is closed, with no trades, and offers various data points and resources related to the company's financials on ", "url": "https://www.tradingview.com/symbols/NASDAQ-AGIO/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-03T11:39:42", "published_display": "03 Jul 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Agios Pharm For: 2 July By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPR0FfUlAtRTdBVE1qZVo5VnlCN3FCbWtIUjE0Y29jTzJhRTlUMm1YTkVnNjFBSzI3amN1bUI1elp3VTB5NUJHUUFZVGFqUDNhajVqUDhoYlVJeF9QVy1tc0ZjN1lraEE2dTRaREpoUkFGa0UzTTBOV0treThIRWYtLWpReXNoN2pQa2ZrQ0Fzc3gzY0d6?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-07-02T22:02:56+00:00", "published_display": "02 Jul 2026 22:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agios Pharmaceuticals: CMO Sarah Gheuens sells $150,502 in stock By Investing.com", "summary": "Sarah Gheuens, CMO of Agios Pharmaceuticals, sold 4,007 shares of company stock worth $150,502 to cover tax obligations related to restricted stock unit vesting. This transaction followed a 10b5-1 trading plan established in 2023. Gheuens simultaneously acquired 8,375 shares thro", "url": "https://ca.investing.com/news/stock-market-news/agios-pharmaceuticals-cmo-sarah-gheuens-sells-150502-in-stock-93CH-4718904", "source_name": "Investing.com Canada", "published_at": "2026-07-02T20:11:49", "published_display": "02 Jul 2026 20:11", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agios (NASDAQ: AGIO) CMO nets shares after RSU vesting and tax sale", "summary": "Agios Pharmaceuticals' Chief Medical Officer, Sarah Gheuens, reported a routine equity transaction where 8,375 restricted stock units vested and converted into common shares. To cover tax obligations, 4,007 shares were sold at $37.56 each under a pre-arranged 10b5-1 plan. Followi", "url": "https://www.stocktitan.net/sec-filings/AGIO/form-4-agios-pharmaceuticals-inc-insider-trading-activity-b939195679ee.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:09:49", "published_display": "02 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "D. E. Shaw reports 3.03M-share stake in Agios (AGIO)", "summary": "D. E. Shaw & Co., L.P. and David E. Shaw have reported a 5.1% stake in Agios Pharmaceuticals (AGIO), totaling 3,034,031 shares, through a Schedule 13G SEC filing. The filing indicates shared voting power over 2,863,931 shares and shared dispositive power over all 3,034,031 shares", "url": "https://www.stocktitan.net/sec-filings/AGIO/schedule-13g-agios-pharmaceuticals-inc-passive-investment-disclosure--4fb451f2ba1d.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:09:49", "published_display": "02 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AGIO (NASDAQ: AGIO) affiliate notifies plan to offer 4,007 shares via broker", "summary": "An affiliate of Agios Pharmaceuticals (NASDAQ: AGIO) has filed a Form 144, indicating a plan to offer 4,007 shares of common stock. These shares are associated with the vesting of restricted stock units on July 1, 2026, and will be sold through Morgan Stanley Smith Barney LLC. Th", "url": "https://www.stocktitan.net/sec-filings/AGIO/144-agios-pharmaceuticals-inc-sec-filing-6eb6c2d7e508.html", "source_name": "Stock Titan", "published_at": "2026-07-01T19:41:17", "published_display": "01 Jul 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Agios Pharmaceuticals' Shift Into Russell Growth Indices Will Impact Agios Pharmaceuticals (AGIO) Investors", "summary": "Agios Pharmaceuticals (AGIO) has been added to several Russell growth benchmarks, including the Russell 2000 Growth, indicating an increasing perception of the company as a growth-oriented biotech. This reclassification could attract more growth-focused institutional investors an", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agio/agios-pharmaceuticals/news/how-agios-pharmaceuticals-shift-into-russell-growth-indices/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-01T08:41:17", "published_display": "01 Jul 2026 08:41", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agios (NASDAQ: AGIO) director exercises RSUs and gains new equity awards", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOXzZjUlhjaTlTdk5YZW1SM09FVmR3dVZkam05TWlTekM4dk1mTDRhR09sR29UbHlJMElSSFV5T05YelAxc0NGYkJWTDVxZ19MUmttRmRrVVhrUW1vYlpjSWRvM3JKOUNXS0FDbV9ZelNhSGowb3o3TkltUzBqYzFTTENjY05VN2d4SUUwaVhDbjNpSV9GaC1RYmVXSVp6ZGR6MG5VUExveGlTczlxSjBRRUlzOS1mMDdDNXo0?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Agios Pharmaceuticals (AGIO) Valuation After Recent Share Price Volatility", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNNWZDVzRRdFhPdUNuajRBTGdab2tWdXBqMU5od3l5X1NVZndKQXo5eGNQaExPSF8wNGJVbElzSC0wSlpJdjJ4ZlNGRWpDcnUzcWZMMEw4ekJNMGVEcnZBSDRxT1ZrcmczRWp5R2JLQ1BZMEpGRVI2SlBJV2JvQkdjc1lNTlAwQmJQWEtXN2tvblV6OTBpQ3daRHdXQ3VtbExfZHVxcTQwckhCeVFlbXpIag?oc=5", "source_name": "Market source", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agios submits application for mitapivat in sickle cell disease", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOcllsby0zMFpBUjVtaUdDS3lOQUhxQzdaTjNyUmtndWU1SG1DeUhYYnUyMXloaXV1OFJjXzdMa0VxdDZGYWhWYUF0VTlUUVBRRTRlMnY3Z3l3eUF4YVhYcW1wYlZpMzdEWVJkdV9iTFdSeHhQRGhaWnI3eFIweldBSTh5QklVMmJxb3Z1MWtsQ1ZrZXZNV2ZldEJJNUo4TlNHS0xfeVExMFQ1d1lwR3ZsbFZlNVdXYWJzWkhn?oc=5", "source_name": "Investing.com", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agios presents mitapivat data at European hematology congress", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxObFVNb2FiQVZjNG5XODhNY1BpU05NOXBnQWxUR25qT2VmaUNCRTZGeUE3eThrY09NaEM0OU5QU0N4X1h5YWpyeFl1MGdWaHJTV3hnOFQ4Y1VsTjc5dXZfWDdMV2hMQldlcktQNEloUXN3LU1UQ05xdHdacExQRHhINWFRM2YwUFE1WjJLei11dzdfR3IzTmFvVm5Qb250bXNtdjNJVTIzM0MwYTJENUVPT0pVdHpIQVQ4THc?oc=5", "source_name": "Investing.com", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agios Pharmaceuticals stock tumbles 25% after Novo data", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNMkZZMHByQ1JydDhyOFFsdkFVY1hIVGl6dXFkSzZ2RWZ2U25FQWxxTFFWSHA5VzNHby1sOVlseXFZanZuTVBiU25CckZ6YXJwaV9yQzZDMTl2cTMtYmFoOW96UGo4TnA5M3BVTjFjdUZZSGlDZDU1akl5RzlMaWRVejJHX2h4S01tc19ya01vLUk0azFpOEt6S1RfU3lCYWktVHRJM3VKdVdmWFhiOThlcA?oc=5", "source_name": "Investing.com", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why Agios Pharmaceuticals Crashed 23% Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPTFhIUTFtdjVxZ1lvcm5rdzFSS2dGaVNBZjdBNTF4TUV6Njc3WEljbkFqVWl2a2JRdk9ZMVlCU3NlLXZrQndJV3lPZDdvOUF3d1Znc0FmX01ybERCTnpHbWx6SldvR2xQNWRfVHNkSGlmWkw3c3B1VXd4M1ZyZUFTaWtkeS1WUkpvU3dwM2ZESkZkREpzNXc?oc=5", "source_name": "The Motley Fool", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Agios Pharm Q4 2024 beats EPS forecast, stock rises", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxQVTQ2S0huX2dvUkVwTEFZTEJoZmJ6c1hkcDV3VUl5a0k5eXlxY2hoS2VfbDdsLUJCaFlBODFFTVVoeWF5R1pvc2tpMWlPcjI2R0NaVVhXb0JNNVdBeE5HbWJ2clBHYm90YzRuUFJSSTFvaWpUVnc0Q243dnZqenZmSzUyY3pDMXI5dW9jVUVGVFpmbWNyMXlVSHFWNW4wWWo4U0xmZzRXaldxbDZVQ3VnZ3NQeUZTN08yTkQ3TFhXQlNKSTFncFFxRUVB?oc=5", "source_name": "Investing.com UK", "published_at": "2025-02-13T08:00:00+00:00", "published_display": "13 Feb 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxQSW9mM3I5d1lnaHgzVDlPNFgzSVg3MFNNVmk0N0hLcGh3dko0MF9kWUVzS1phTmdDU1NjUGFZamZZWTBmdnFfanllME9NWmhxd0JiMjJzM3JCQU9SVnY0cEx3T3JnT1pDUlh3Vy0xR1lDem9hZ2ZqdUFXd2UzU1JRbkczUEdHZ1hSRGdTN1JfSHgtLUxQVTBJRjNGbS15Z05pZVd0a25wZl9OX0VjNnp4WHVVOUxxeUVwbTJ1TmdMTzZvcEZVbTkzSDdEUFhvZTdtZC1fb3R2SFZ4ZzQ?oc=5", "source_name": "StockStory", "published_at": "2026-07-15T07:00:00+00:00", "published_display": "15 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 86, "total_relevant": 49, "sentiment_summary": {"positive": 21, "negative": 1, "neutral": 27, "score": 59, "total": 49, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 81, "events": [{"event": "general", "label": "Market update", "weight": 15.4, "count": 28}, {"event": "earnings", "label": "Earnings", "weight": 5.36, "count": 12}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 1.1, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 21, "negative_events": 1}, "market_context": {"has_market_context": true, "latest_close": 41.23, "latest_week": "2026-07-10", "one_week_move": 9.7, "four_week_move": 40.0, "twelve_week_move": 17.3, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.095551, "market_dynamics_buy_signal": false, "relative_strength": 6.630703, "fair_value_gap": 23.2, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 51.3528, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+9.7% over one week, +40.0% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 69, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 8}, {"label": "Stock Titan", "count": 6}, {"label": "TradingView", "count": 5}, {"label": "Investing.com", "count": 4}, {"label": "Simply Wall Street", "count": 3}, {"label": "The Motley Fool", "count": 2}, {"label": "Moomoo", "count": 2}, {"label": "simplywall.st", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 40}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 28}, {"label": "Earnings", "count": 12}, {"label": "Analyst action", "count": 4}, {"label": "Regulatory and legal", "count": 2}, {"label": "Guidance", "count": 2}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "59/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "81/100 classification confidence."}, {"label": "Company focus", "value": "40", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+9.7% over one week, +40.0% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Agios Pharmaceuticals (AGIO) Wins Priority Review, Is The Stock Now Fully Valued?"}], "updated_at": "2026-07-16T18:00:12.800539+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}